Articles tagged with Pulmonary Hypertension
Researchers have identified PFKFB3 as a key player in the development of pulmonary hypertension, a condition characterized by high blood pressure in the lungs. By targeting this enzyme, scientists hope to develop new treatments that can help alleviate symptoms and improve patient outcomes.
Researchers have identified FoxM1 as a potential target for treating pulmonary hypertension, a severe lung disease with a 50% five-year survival rate. Deleting the FoxM1 gene in mice resulted in thinner artery walls and improved right heart function.
Scientists at Johns Hopkins Medicine have made significant breakthroughs in understanding the underlying biology behind pulmonary hypertension. By studying endothelial cells, they discovered that KLF15 protects these cells from damage caused by low oxygen levels, which can lead to blood vessel damage and progression of the disease.
A study published in Science Translational Medicine found that lung cancer often leads to pulmonary hypertension due to immune cell activation and inflammatory processes triggered by cancer cells. This discovery could lead to new therapeutic approaches for developing a treatment.
A study found that sildenafil increased the risk of hospitalization and death in patients with valvular heart disease and residual pulmonary hypertension. The drug should be avoided in these cases.
A systematic review of PDE-5 inhibitor use in pediatric patients with pulmonary hypertension found improvements in oxygenation, hemodynamics, and clinical outcomes. The evidence suggests that low- and moderate-dose sildenafil are safe regimens for children, outweighing the risks associated with long-term use.
A new study suggests that pretreating red blood cells with nitric oxide can reduce the risk of pulmonary hypertension, a life-threatening condition associated with transfusions. Pretreated RBCs showed improved survival and function after transfusion, outperforming stored RBCs not exposed to nitric oxide.
A new mouse model of bronchopulmonary dysplasia has been developed to study pulmonary hypertension, enabling the detection of the disease at an earlier time point through echocardiography tests. This breakthrough could lead to improved diagnoses and more effective treatments for premature infants.
Researchers have found increased expression of galectin-3 protein in pulmonary hypertension, which causes unhealthy remodeling and constriction of lung blood vessels. They also discovered that a drug already tested for liver fibrosis can block or reverse early disease progression, offering new hope for treatment.
Researchers discovered that pulmonary artery stiffening occurs early in the disease process and promotes vascular remodeling by altering signaling pathways. This finding highlights the importance of addressing pulmonary artery stiffness as an early driver of pulmonary hypertension.
A rare form of pulmonary hypertension has been discovered in dogs, with similar symptoms and potentially useful as a model for human PVOD. The study, published in Veterinary Pathology, could lead to new insights into the disease and its treatment options.
Selexipag, an orally available selective prostacyclin IP receptor agonist, demonstrates effectiveness in treating pulmonary hypertension, reducing hospitalizations by 40%. The medication targets a well-known disease pathway, improving heart function and opening blood vessels to the lungs.
MicroRNAs, specifically miR-125a, control endothelial cell proliferation and are increased in lung tissue of hypoxia-exposed animals. Inhibition of miR-125a increases expression of tumor suppressor genes, reducing cell proliferation.
Dr. Ronald Oudiz, a renowned researcher at LA BioMed, is being recognized for his pioneering work in the pulmonary hypertension field. His contributions have led to significant advancements in understanding and treating this potentially fatal disease.
A meta-analysis by UT Southwestern Medical Center cardiologists found exercise training reduces pressure in the arteries and increases exercise tolerance in patients with pulmonary hypertension. The study also showed a positive effect on several measures of heart function and overall quality of life, without compromising safety.
The new guidelines introduce a novel treatment algorithm for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), recommending sequential and initial combination therapies based on patient risk profiles. The guidelines also provide updated classifications, diagnostic algorithms, and assessmen...
Researchers aim to optimize aerobic exercise training for patients with pulmonary arterial hypertension, which could improve blood pressure in the lungs, skeletal muscle, and heart metabolism. High-intensity interval training has shown promising results in reversing enlargement of the right ventricle and improving blood pressures.
A new study documents a substantial increase in US children's pulmonary hypertension hospitalizations over 15 years, resulting in significant cost increases. The study also found that hospitalizations are now more common among children without congenital heart disease.
Researchers developed a lightweight system to produce therapeutic nitric oxide from the air using an electric spark, overcoming size and cost limitations of existing equipment. The device shows promise for treating conditions like pulmonary hypertension, chronic lung diseases, and certain types of heart failure.
Researchers at UGA have discovered a potential treatment for pulmonary fibrosis and pulmonary hypertension using the drug triciribine. The study shows that triciribine can halt disease progression and may even reverse some of the damage to lung tissue.
A genetic mutation in cattle grazing at high altitude leads to a life-threatening condition called brisket disease, characterized by high blood pressure in the lungs. The study sheds light on human lung disease, particularly non-familial pulmonary hypertension in patients with emphysema and pulmonary fibrosis.
A UAlberta team discovered a protein linked to metabolic regulation is critical in pulmonary hypertension development. Lower levels of Sirtuin3 have been found in patients with the disease, and gene therapy approaches show promise for improving symptoms.
Researchers identified FoxO1 as a key molecule regulating cell division in vascular wall cells, leading to pulmonary hypertension. Boosting FoxO1 activity has been shown to normalize pathological cell division and potentially cure the disease in rats.
Researchers discovered using plants to produce an enzyme may improve treatment for life-threatening lung high blood pressure. The study found that replenishing ACE2 protein helped decrease pulmonary blood pressure and increase pulmonary blood flow in rats.
Researchers discovered two potential therapeutic targets to treat pulmonary arterial hypertension, a deadly disease marked by high blood pressure in the lungs. The targets involve suppressing abnormal proliferation of smooth muscle cells and signaling molecules involved in the disease.
Researchers discovered a peptide mimicking high-density lipoprotein (HDL) protein helps reduce oxidized lipids in pulmonary hypertension, improving heart and lung function. The study also found elevated levels of oxidized proteins in rodents with the disease, which can be targeted for treatment development.
A study published in The Journal of Clinical Investigation reveals that the miR-130/301 microRNA family regulates diverse target genes, orchestrating a global proliferative response in diseased blood vessels. This discovery provides new therapeutic targets for treating pulmonary hypertension.
A novel guanylate cyclase stimulator improved exercise capacity and hemodynamics in patients with inoperable or recurrent CTEPH, closing a therapeutic gap. The drug was well-tolerated and showed significant improvements in six-minute walking distance.
A study of over 1,100 patients with severe PH found that higher BMI was associated with lower one-year mortality rates, even after adjusting for other factors. The researchers suggest that increased levels of serum lipoproteins in obese individuals may play a role in neutralizing circulating toxins and inflammatory proteins.
A study published by the American Thoracic Society found that patients with pulmonary hypertension from lower socioeconomic groups are diagnosed with more advanced disease states than those from higher income groups. This disparity may result in poorer health outcomes for these patients. The study suggests that limited access to health...
Researchers found that patients with low pulmonary vascular resistance who underwent pulmonary thromboendarterectomy had lower mortality rates and fewer complications compared to those with high pulmonary vascular resistance. Additionally, these patients experienced shorter hospital stays and improved recoveries.
The new guidelines recommend regular screening for pulmonary hypertension in SCD adults, and intensifying SCD therapy for those with PH. Patients with symptomatic PH should be treated, while management is guided by hemodynamic numbers obtained through catheterization.
The American Thoracic Society has developed guidelines to identify and manage patients with sickle cell disease who are at increased risk of mortality from pulmonary hypertension. Guidelines recommend treatment with hydroxyurea, chronic transfusion therapy, or indefinite anticoagulant therapy in patients with confirmed pulmonary hypert...
A study published in Cell Reports reveals how excess smooth muscle cells develop in arteries affected by pulmonary hypertension, a potentially fatal disease. The research provides new insights into the disease's progression and may lead to novel treatments targeting specific cell types.
Researchers at Yale University have made a breakthrough in understanding the cellular mechanisms behind pulmonary hypertension, a life-threatening condition that affects millions. The study identified specific cells responsible for the disease's progression and suggests potential targets for therapy.
A Stanford study found that blocking an inflammation-producing molecular pathway reverses pulmonary hypertension in rats, suggesting a potential cure for the deadly disease. The research could also lead to better understanding of other inflammatory diseases.
At high altitudes, pulmonary hypertension develops as a normal adaptive response but can become life-threatening if exaggerated. Research highlights the need for targeted drug therapy, with potential new directions emerging in understanding epigenetic mechanisms and their role in disease
Research reveals a significant increase in US pulmonary hypertension deaths and hospitalizations from 1999-2009, with higher rates observed among women and older adults. Death rates were also higher for blacks than whites, and hospitalization rates varied by region.
Inhibition of PBEF has been shown to prevent and reverse monocrotaline-induced pulmonary hypertension in rats, suggesting its potential as a therapy. The study's findings imply that targeting PBEF activity could provide a new approach to treating patients with PH.
Researchers have discovered a critical protein called calpain that contributes to the development of pulmonary hypertension in adults. Blocking this protein may prove effective in preventing narrow, scarred blood vessels and treating the condition.
Researchers at UCLA found that estrogen treatment can reverse the progression of pulmonary hypertension to heart failure and restore lung and ventricle structure and function. The study suggests that even short-term estrogen therapy may suffice to reverse the disease, offering new potential therapeutic applications for human patients.
Researchers have discovered a protein called PIM-1 that can serve as an early warning system for pulmonary hypertension, allowing for earlier diagnosis and potentially more effective treatment. Gene therapy has also been shown to reverse the condition by blocking the inappropriate activation of this protein.
Researchers at U of Alberta have found a potential treatment for pulmonary hypertension by targeting the mitochondria in lung blood vessel cells. They discovered that dichloroacetate and trimetazidine can increase mitochondrial activity, inducing cell death and regressing the disease in animal models.
Researchers found that increasing BMPR2 levels reduced pulmonary hypertension and strain on the heart in rat models of the disease. The study suggests that boosting BMPR2 levels could offer a new therapeutic target for treating PAH.
Endothelin receptor antagonists have shown benefits in treating pulmonary hypertension, resistant arterial hypertension, and proteinuric renal disease. These drugs work by blocking the effects of endothelin-1, a potent vasoconstrictor that can contribute to various diseases.
The new guidelines identify six different clinical groups of pulmonary hypertension, with a focus on treatment strategies and risk stratification. Pulmonary arterial hypertension (group 1) is the only group provided with specific drug therapy and an evidence-based treatment algorithm.
The NHLBI has stopped a clinical trial testing sildenafil for pulmonary hypertension in adults with sickle cell disease due to increased risk of severe pain crises and hospitalization. The study found that participants taking sildenafil were more likely to experience serious medical problems compared to those on placebo.
New research shows tadalafil, an erectile dysfunction drug, effectively treats pulmonary arterial hypertension (PAH) by improving six of eight short form-36 domains and reducing pulmonary artery pressures. The study also reveals PAH diagnosis has increased by 10 months and affects women more in middle age.
Researchers at University of Cincinnati are studying variations of rare lung disease Lymphangioleiomyomatosis (LAM) to better understand its manifestations and develop more effective treatments. The study will compare patients with and without pulmonary hypertension to identify key differences in symptoms.
Researchers at the University of Chicago Medical Center report positive results from a human trial of sorafenib, a cancer drug, as a treatment for pulmonary hypertension. Eight out of nine patients improved their exercise capacity and six experienced significant improvements in right ventricular ejection fraction.
Researchers at the University of Granada have developed a new system to diagnose pulmonary hypertension earlier. The system uses ultrasound technology and measures pulmonary artery systolic pressure, allowing doctors to identify the condition before it becomes irreversible.
Researchers at Johns Hopkins Medicine found that heart transplant recipients who receive commonly used blood-vessel-opening drugs can achieve similar survival rates as those without high pressure. The study of 10,331 patients showed a reduced survival rate for those who did not respond to therapy. These findings bring new hope to hundr...
Researchers at the University of Alberta have discovered a central command system for pulmonary hypertension, a disease with no cure and high mortality rate. The team identified nuclear-factor-of-activated-T-lymphocytes (NFAT) as a potential controlling element in the cause of the disease.
Researchers found that sorafenib can prevent pulmonary hypertension development in rodents by inhibiting abnormal cellular growth and new blood vessel formation. The study suggests a potential therapeutic option for this cardiovascular disease.
A single dose of sildenafil prevented rebound pulmonary hypertension and reduced mechanical ventilation time in ICU infants undergoing nitric oxide withdrawal. The study found significant benefits for the sildenafil group, with a total ICU stay of 47.8 hours compared to 189 hours for placebo recipients.
Researchers developed a simple, noninvasive test to measure right ventricular function and predict survival of adults with pulmonary hypertension. The test, TAPSE, assesses echocardiographic abnormalities in the tricuspid valve and showed that patients with advanced right ventricular dysfunction had dramatically reduced survival rates.
A hormone called BNP detects pulmonary hypertension in sickle cell disease patients and predicts mortality. High BNP levels correlate with greater pressure in pulmonary arteries and increased risk of death.
A study found that elevated BNP levels are associated with increased mortality and significant pulmonary hypertension in patients with chronic lung disease. Pulmonary artery pressure above 35 mmHg is a key indicator of this condition.
PULMOTENSION aims to uncover underlying molecular pathways of PH, identify distinct targets for anti-remodelling therapy and test new treatment options in preclinical and clinical trials. The combined expertise in PULMOTENSION extends from gene mutation discovery to therapeutic regimen establishment.
Gleevec has been found to reverse lung vascular remodeling and pulmonary hypertension in experimental models. Larger clinical trials are planned to test its safety and effectiveness.